Jounce Therapeutics Stock Cash Per Share
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Jounce Therapeutics fundamentals help investors to digest information that contributes to Jounce Therapeutics' financial success or failures. It also enables traders to predict the movement of Jounce Stock. The fundamental analysis module provides a way to measure Jounce Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jounce Therapeutics stock.
Jounce |
Jounce Therapeutics Company Cash Per Share Analysis
Jounce Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Jounce Therapeutics Cash Per Share | 2.87 X |
Most of Jounce Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jounce Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Jounce Therapeutics has a Cash Per Share of 2.87 times. This is 34.02% lower than that of the Biotechnology sector and 33.72% lower than that of the Health Care industry. The cash per share for all United States stocks is 42.71% higher than that of the company.
Jounce Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jounce Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jounce Therapeutics could also be used in its relative valuation, which is a method of valuing Jounce Therapeutics by comparing valuation metrics of similar companies.Jounce Therapeutics is currently under evaluation in cash per share category among its peers.
Jounce Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X | |||
| Price To Book | 0.27 X | |||
| Price To Sales | 7.27 X | |||
| Revenue | 82 M | |||
| Gross Profit | 27.2 M | |||
| EBITDA | (50.16 M) | |||
| Net Income | (50.92 M) | |||
| Cash And Equivalents | 148.56 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.89 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.78 X | |||
| Book Value Per Share | 3.54 X | |||
| Cash Flow From Operations | (28.88 M) | |||
| Short Ratio | 0.48 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 141 | |||
| Beta | 0.75 | |||
| Market Capitalization | 101.59 M | |||
| Total Asset | 212.55 M | |||
| Retained Earnings | (292.79 M) | |||
| Working Capital | 173.66 M | |||
| Current Asset | 103.95 M | |||
| Current Liabilities | 51.26 M | |||
| Z Score | 3.78 | |||
| Net Asset | 212.55 M |
About Jounce Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jounce Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jounce Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jounce Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |